The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

BACKGROUND: Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of angiogenesis are attractive targets for therapy. Vascul...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Dineen, Sean P, Sullivan, Laura A, Beck, Adam W, Miller, Andrew F, Carbon, Juliet G, Mamluk, Roni, Wong, Henry, Brekken, Rolf A
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2008
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2627916/
https://ncbi.nlm.nih.gov/pubmed/19038046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-352
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires